First Pancreatic Cancer Patient in Europe treated with Alpha DaRT® in French Multicenter ACAPELLA Clinical Trial April 28, 2026
FDA Fast Track Designation for BBO-11818 for Advanced KRAS-Mutant Pancreatic Ductal Adenocarcinoma April 28, 2026
Daraxonrasib Demonstrates Unprecedented OS Benefit in Ph 3 RASolute 302 Clinical Trial in Patients with Metastatic Pancreatic Cancer April 21, 2026
Nature Medicine Publishes Results Showing Doubling of the Rate of Survival with Elraglusib + Chemo in 1L Metastatic Pancreatic Ductal Adenocarcinoma April 21, 2026
Recruitment in AMPLICITY trial halted after three Dose Limiting Toxicities (DLTs) related to mFOLFIRINOX April 15, 2026
First Patient Dosed in Ph 3 RASolute 303 Trial of Daraxonrasib in 1L Metastatic Pancreatic Cancer April 7, 2026
Positive Topline Results from Ph 2 PANOVA-4 Trial of Tumor Treating Fields (TTFields) Therapy for Metastatic Pancreatic Cancer Announced March 31, 2026
Israeli Ministry of Health approves initiation of Ph 2/3 trial of SIL204 for the treatment of locally advanced pancreatic cancer March 31, 2026
Mature median OS data from ongoing ACCENT clinical trial of narmafotinib + chemo in advanced pancreatic cancer announced March 24, 2026
Positive End-of-Phase 2 Meeting with FDA Regarding the Design of a Ph 3 Trial of VCN-01 in Metastatic Pancreatic Ductal Adenocarcinoma Announced March 24, 2026
Erasca and Tango Therapeutics to Evaluate Combination of ERAS-0015 and Vopimetostat in MTAPdel pancreatic or MTAPdel RASm NSCLC March 10, 2026
AIM ImmunoTech Announces Expiration and Preliminary Results of its Rights Offering for Aggregate Gross Proceeds of $1.8M March 10, 2026
Agreement Signed for Planning of Proposed Ph 3 Trial of Ampligen for Late-Stage Pancreatic Cancer March 10, 2026
FDA approves IND application for KST-0651 for Ph 1 trial in Advanced Solid Tumors including pancreatic cancer, CRC, NSCLC, and others March 10, 2026
AIM ImmunoTech Signs Agreement for Planning of Proposed Ph 3 Trial of Ampligen in Late-Stage Pancreatic Cancer March 3, 2026
Planned Milestones in Ongoing Ph 2 DURIPANC Trial of Ampligen and Durvalumab in the Treatment of Metastatic Pancreatic Cancer Announced February 25, 2026
US FDA Approves Novocure’s Optune Pax® for the Treatment of Locally Advanced Pancreatic Cancer February 17, 2026
Positive Year-End Interim Clinical Progress from Ph 2 Study of Ampligen – Imfinzi Combo in Pancreatic Cancer Reported February 9, 2026
First Patient Dosed in Ph 1 Trial of RMC-5127 in patients with RAS G12V–mutated solid tumors February 1, 2026
Continued Zenocutuzumab Treatment Beyond Progression Shows Benefit in Patients with NRG1+ Pancreatic Cancer and Cholangiocarcinoma from the eNRGy Trial January 18, 2026
Positive Follow-Up Data from Ph 2 Trial Shows Extended Long-Term OS Benefit with Elraglusib + Chemo for Metastatic Pancreatic Cancer January 18, 2026
